The newly licensed compounds, developed at the University of Wisconsin-Milwaukee, act on a particular neurotransmitter receptor in the brain, which has shown promise for treatment of epilepsy and other convulsant disorders.
news, journals and articles from all over the world.
The newly licensed compounds, developed at the University of Wisconsin-Milwaukee, act on a particular neurotransmitter receptor in the brain, which has shown promise for treatment of epilepsy and other convulsant disorders.